Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Indication assessment · Neuropsychiatric

Sleep initiation and maintenance disorders — indication assessment

Difficulty initiating or maintaining sleep with daytime consequences, assessed by polysomnography, actigraphy or validated questionnaires.

Document identifier
CEI-IN-26
Series
Indication assessment
Version
1.3
Published
18 Oct 2024
Last reviewed
18 Oct 2024
Next review
18 Oct 2026
Identifier
10.71829/cei.ind.26
Certainty
Not rated
Cycle
2024 Q4
ICD-11
7A00
Category
Neuropsychiatric

§1Assessment

§1.1Definition

Difficulty initiating or maintaining sleep with daytime consequences, assessed by polysomnography, actigraphy or validated questionnaires.

§1.2Anchor and additional outcomes

The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.

  1. Sleep-onset latency
  2. Wake after sleep onset
  3. Total sleep time
  4. Pittsburgh Sleep Quality Index

§1.3State of the evidence

Distribution of certainty ratingsShare of assessed outcomes at each certainty level.2compounds
HighModerateLowVery low
Figure 1. Certainty ratings across the 2 compounds the Institute assesses for this indication. A high rating for one compound says nothing about another.

The Institute assesses 2 compounds in this indication, drawing on 2 trial records and 0 evidence syntheses. No compound is graded above low certainty in this indication, which the Institute records as the principal finding for it.[1,2]

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
  2. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.